Acellera
Acellera Therapeutics is a drug discovery company leveraging AI and quantum chemistry solutions for early-stage drug discovery. Their platform, QuantumBind®, focuses on small-molecule discovery and potency optimization by combining quantum chemistry accuracy with AI/ML speed. They aim to enhance drug discovery capabilities by shortening the time to identify lead molecules, taking programs from target to a prioritized list of leads within weeks. Acellera has partnered with numerous top pharma and biotech companies worldwide, applying their technology to complex challenges in drug discovery. The company was founded in 2023 in the USA and was among the first to use GPUs for molecular dynamics, and is now leading in integrating machine learning into the drug discovery pipeline. They are seeking partners and funding in 2025 to achieve their ambitious goals.
Acellera
Acellera Therapeutics is a drug discovery company leveraging AI and quantum chemistry solutions for early-stage drug discovery. Their platform, QuantumBind®, focuses on small-molecule discovery and potency optimization by combining quantum chemistry accuracy with AI/ML speed. They aim to enhance drug discovery capabilities by shortening the time to identify lead molecules, taking programs from target to a prioritized list of leads within weeks. Acellera has partnered with numerous top pharma and biotech companies worldwide, applying their technology to complex challenges in drug discovery. The company was founded in 2023 in the USA and was among the first to use GPUs for molecular dynamics, and is now leading in integrating machine learning into the drug discovery pipeline. They are seeking partners and funding in 2025 to achieve their ambitious goals.